卵巢恶性肿瘤雌激素受体及孕激素受体的研究  

Estrogen and Progesterone Receptors in Ovarian Malignant Tumor

作　　者：史锦兰[1] 陈萍倩[1] 张蓉[1] 陆以农[1] 

机构地区：[1]江苏无锡市妇幼保健院,无锡市214002

出　　处：《中国肿瘤临床》1994年第5期352-354,363,共4页Chinese Journal of Clinical Oncology

摘　　要：应用酶联雌二醇(E_2—HRP)和酶联孕酮(Pg—HRP)亲和组化法检测卵巢恶性肿瘤雌激素受体(ER)和孕激素受体(PgR)45例,结果ER阳性35例,PgR阳性33例,其阳性检出率依次为77％和73％.不同类型肿瘤的受体水平有差异,上皮性癌肿的阳性检出率较转移癌高.检测结果显示:肿瘤分化越好,受体水平也越高.早期癌比晚期癌的ER、PgR受体水年高.受体阳性者术后加用他莫西芬(Tamoxifen)联合化疗治疗,其生存时间较阴性者长,复发亦晚.提示ER、PgR水平高低可作为选择内分泌治疗和预测病人预后的参考指标.Using E2-HRP and Pg-HRP immunohistochemical technique in 45 eases of malignant tumor of the o-vary ER and PR were tested with positive rates of 77% and 73% respectively. The ER and PgR levels in epithelial cancer of the ovary were higher than those of other pathologic type ovarian tumors and it was lowest in metastatic tumors. The results also showed that the better the differentiation of the cancer cells the higher of the level of the ER and PgR contentswere.

关 键 词：雌激素 孕激素 受体 卵巢肿瘤 癌 

分 类 号：R737.310.3[医药卫生—肿瘤]